0001104659-21-061700.txt : 20210505 0001104659-21-061700.hdr.sgml : 20210505 20210505160424 ACCESSION NUMBER: 0001104659-21-061700 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20210505 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20210505 DATE AS OF CHANGE: 20210505 FILER: COMPANY DATA: COMPANY CONFORMED NAME: OCULAR THERAPEUTIX, INC CENTRAL INDEX KEY: 0001393434 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36554 FILM NUMBER: 21893158 BUSINESS ADDRESS: STREET 1: 24 CROSBY DRIVE CITY: BEDFORD STATE: MA ZIP: 01730 BUSINESS PHONE: 781-895-3235 MAIL ADDRESS: STREET 1: 24 CROSBY DRIVE CITY: BEDFORD STATE: MA ZIP: 01730 FORMER COMPANY: FORMER CONFORMED NAME: I-THERAPEUTIX INC DATE OF NAME CHANGE: 20070315 8-K 1 tm2115217d1_8k.htm FORM 8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 5, 2021

OCULAR THERAPEUTIX, INC.

(Exact Name of Company as Specified in Charter)

Delaware		001-36554		20-5560161
(State or Other Jurisdiction of Incorporation)		(Commission File Number)		(IRS Employer Identification No.)

24 Crosby Drive

Bedford, MA 01730

(Address of Principal Executive Offices) (Zip Code)

Company’s telephone number, including area code: (781) 357-4000

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.0001 par value per share		OCUL		The Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 2.02

Results of Operations and Financial Condition.

On May 5, 2021, Ocular Therapeutix, Inc. announced its financial results for the quarter ended March 31, 2021. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

The information in this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is furnished to comply with Item 2.02 of Form 8-K, and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 9.01

Financial Statements and Exhibits.

(d)

Exhibits:

	99.1	Press Release of Ocular Therapeutix, Inc., dated May 5, 2021

	104	Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	OCULAR THERAPEUTIX, INC.

Date: May 5, 2021	By:	/s/ Donald Notman
		Donald Notman
		Chief Financial Officer

EX-99.1 2 tm2115217d1_ex99-1.htm EXHIBIT 99.1

Exhibit 99.1

Ocular Therapeutix™ Reports First Quarter 2021 Financial Results and Business Update

DEXTENZA^®Achieved Quarterly Record of 16,634 Billable Units Sold to End Customers, Representing Quarterly Sequential Growth of 15%.

BEDFORD, Mass.--(BUSINESS WIRE)— May 5, 2021 -- Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today reported financial results for the first quarter of 2021, and provided updates on its strong ophthalmology pipeline.

“Our progress in the first quarter of 2021 was significant,” said Antony Mattessich, President and Chief Executive Officer. “Revenue for DEXTENZA^® was up over 200% against the prior year period and we achieved record quarterly, in-market sales in excess of 16,000 billable units, representing 15% sequential quarterly growth. Encouragingly, the momentum we saw in the first quarter has continued into the second quarter with estimated sales in excess of 8,000 billable units in April alone. Beyond DEXTENZA, we have made progress in advancing our pipeline of product candidates that continue to show potential to set the standard of care in their respective disease areas. We have had a large presence at this year’s ongoing ARVO meeting with seven total presentations highlighting both pre-clinical and clinical updates in our key programs. In 2021 we look forward to continued momentum with DEXTENZA and further development of our pipeline which includes the planned initiation of two Phase 2 programs in wet-AMD and glaucoma and the expected completion of a Phase 2 clinical trial in dry eye disease.”

Recent Business Updates

Presented Pre-Clinical and Clinical Data at the 2021 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting. Six company presentations and one presentation from an investigator-initiated trial are being held at the 2021 Association for Research in Vision and Ophthalmology (ARVO) Virtual Meeting this week. Updated interim analyses of Phase 1 data for both OTX-TKI for the treatment of wet age-related macular degeneration (wet AMD) and other retinal diseases and OTX-TIC for the reduction of intraocular pressure in patients with primary open-angle glaucoma or ocular hypertension were presented. Both presentations provided additional data that continue to support the development of products that could become the standard of care in these large markets.

Data are also being presented on the Company’s products targeting ocular surface disease including pre-clinical pharmacokinetic data on OTX-CSI for the chronic treatment of dry eye disease and OTX-DED for the short-term treatment of signs and symptoms of dry eye disease. Additionally, we are presenting a post-hoc analysis of data on DEXTENZA^®(dexamethasone ophthalmic insert) for the treatment of allergic conjunctivitis. The use of DEXTENZA in allergic conjunctivitis is currently under U.S. Food and Drug Administration (FDA) review with a target action Prescription Drug User Fee Act (PDUFA) date of October 18, 2021. This presentation evaluates the safety of the product candidate across the four clinical trials conducted.

U.S. Commercial Uptake of DEXTENZA. Net product revenue of DEXTENZA^® for the quarter was $6.7 million, an approximately 220% increase over the first quarter of 2020. Net sales for the quarter were flat relative to the previous quarter primarily due to variations in distributor inventory levels. DEXTENZA in-market unit volume to surgery centers, which is the best determinant of true underlying demand, achieved a record in the first quarter of 16,634 billable inserts and grew at approximately 15% sequentially over the previous quarter. As previously reported, January and February in-market billable inserts were 4,582 and 4,901, respectively. In-market demand then rebounded strongly in March with sales of billable inserts achieving a record month of 7,151 units.

The Company is also reporting that April in-market, billable units are estimated to have exceeded 8,000 units, setting a new monthly record.

Dosed First Patient in Phase 2 Clinical Trial Evaluating OTX-DED (dexamethasone intracanalicular insert). The Phase 2 clinical trial is a U.S.-based, prospective, randomized, double-masked, vehicle-controlled, multi-center trial evaluating two different formulations of a new dexamethasone drug product candidate OTX-DED in approximately 150 subjects with dry eye disease. Subjects are to be followed for approximately two months after randomization. This trial is designed to assess the safety and efficacy of OTX-DED for the short-term treatment of signs and symptoms of dry eye disease by evaluating bulbar conjunctival hyperemia, the visual analog score of eye dryness and severity, and total corneal fluorescein staining.

Key Program Updates

·

OTX-TKI (axitinib intravitreal implant) for the potential treatment of wet AMD and other retinal diseases.

o

The Company filed an exploratory IND (eIND) in November 2020 to initiate a Phase 1 clinical trial of OTX-TKI in the United States. A planned U.S.-based Phase 1 clinical trial is anticipated to start in mid-2021.

·

OTX-TIC (travoprost intracameral implant) for the treatment of patients with primary open-angle glaucoma or ocular hypertension.

o

The Company completed enrollment of all four cohorts of its Phase 1 clinical trial.

o

The Company plans to initiate a randomized, double-masked, active-controlled Phase 2 clinical trial in the fourth quarter of 2021 in the United States with a total of approximately 105 subjects to evaluate two different formulations of OTX-TIC versus a control arm receiving Durysta™.

·

OTX-CSI (cyclosporine intracanalicular insert) for the chronic treatment of dry eye disease.

o

The Company has completed enrollment of a U.S.-based Phase 2, randomized, double-masked, multi-center clinical trial to evaluate the safety, efficacy, durability, and tolerability of two different formulations of OTX-CSI versus hydrogel vehicle insert.

o

Top-line data from the Phase 2 clinical trial are expected in the fourth quarter of 2021.

·

OTX-DED (dexamethasone intracanalicular insert) for the short-term treatment of the signs and symptoms of dry eye disease.

o

The Company dosed the first subject in a U.S.-based, prospective, randomized, double-masked, vehicle-controlled, multi-center Phase 2 clinical trial in approximately 150 subjects with dry eye disease.

o

Data from the Phase 2 clinical trial is expected in the first half of 2022.

·

DEXTENZA (dexamethasone ophthalmic insert) 0.4 mg for the treatment of ocular itching associated with allergic conjunctivitis.

o

The FDA has set a target action PDUFA date of October 18, 2021.

·

ReSure^®Sealant is designed to prevent wound leaks in corneal incisions following cataract surgery.

o

The Company has received notification from FDA confirming that the Company has fulfilled all post-approval study requirements for ReSure^® Sealant, with a requirement to update the ReSure label reflecting the study results.

First Quarter Ended March 31, 2021 Financial Results

Gross product revenue net of discounts, rebates, and returns, which the Company refers to as total net product revenue, was $7.3 million for the three months ended March 31, 2021, representing a greater than 175% increase over the first quarter of 2020. Net product revenue of DEXTENZA^®in the first quarter was $6.7 million versus $2.1 million in the comparable quarter 2020 and reflects an approximate 220% increase. Total net product revenue for the first quarter of 2021 also includes net product revenue of $0.6 million from ReSure^® Sealant.

Research and development expenses for the first quarter of 2021 were $10.9 million versus $6.1 million for the comparable period in 2020 primarily driven by increased headcount as well as increased clinical trial costs associated with the ongoing Phase 2 clinical trial for OTX-CSI, the commencement of the Phase 2 clinical trial of OTX-DED and the ongoing Phase 1 clinical trials of OTX-TKI and OTX-TIC.

Selling and marketing expenses in the first quarter of 2021 were $8.1 million as compared to $7.1 million for the same quarter in 2020, primarily reflecting increased personnel costs associated with expansion of the sales force.

General and administrative expenses were $7.7 million for the first quarter of 2021 versus $5.2 million in the comparable quarter of 2020. The increase in expenses stemmed primarily from increased personnel expenses and professional fees.

The Company reported net income of $3.1 million, or a profit of $0.04 per share on a basic basis and a net loss of $(20.8) million, or a loss of $(0.24) per share on a diluted basis in the first quarter of 2021. This compares to a net loss of $(21.5) million, or a loss of $(0.41) per share on a basic and diluted basis for the same period in 2020. As operating expenses increased quarter over quarter, the modest profit was driven by a non-cash gain of $25.0 million related to the change in the fair value of the derivative liability associated with the Company’s convertible notes. This change in fair value was due primarily to a decline in the Company’s common stock price during the first quarter of 2021. Non-cash charges for stock-based compensation and depreciation and amortization were $3.7 million in the first quarter of 2021 versus $2.4 million for the same quarter in 2020.

As of May 1, 2021, the Company had 76.3 million shares outstanding.

As of March 31, 2021, the Company had $209.4 million in cash and cash equivalents versus $228.1 million at December 31, 2020. Based on current plans and related estimates of anticipated cash inflows from DEXTENZA and ReSure product sales and cash outflows from operating expenses, the Company believes that existing cash and cash equivalents, as of March 31, 2021, will enable the Company to fund planned operating expenses, debt service obligations and capital expenditure requirements through 2023. This cash guidance is subject to a number of assumptions including those related to the severity and duration of the COVID-19 pandemic, the revenues and expenses associated with the commercialization of DEXTENZA, and the pace of research and clinical development programs, and other aspects of the business.

Conference Call & Webcast Information

Members of the Ocular Therapeutix management team will host a live conference call and webcast today at 4:30 pm Eastern Time to review the Company's financial results and provide a general business update. The live webcast can be accessed by visiting the Investors section of the Company’s website at investors.ocutx.com. Please connect at least 15 minutes prior to the live webcast to ensure adequate time for any software download that may be needed to access the webcast. Alternatively, please call (844) 464-3934 (U.S.) or (765) 507-2620 (International) to listen to the live conference call. The conference ID number for the live call will be 3944056. An archive of the webcast will be available until August 5, 2021 on the Company’s website.

About Ocular Therapeutix, Inc.

Ocular Therapeutix, Inc. is a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye using its proprietary bioresorbable hydrogel-based formulation technology. Ocular Therapeutix’s first commercial drug product, DEXTENZA^®, is FDA-approved for the treatment of ocular inflammation and pain following ophthalmic surgery. Ocular Therapeutix has received a target action date under the Prescription Drug User Fee Act, commonly known as PDUFA, of October 18, 2021, for a supplemental new drug application to include the treatment of ocular itching associated with allergic conjunctivitis as an additional approved indication of DEXTENZA. Ocular Therapeutix’s earlier stage development assets currently in Phase 1 clinical trials include OTX-TKI (axitinib intravitreal implant) for the treatment of wet AMD and other retinal diseases and OTX-TIC (travoprost intracameral implant) for the reduction of intraocular pressure in patients with primary open-angle glaucoma or ocular hypertension. Ocular Therapeutix is currently evaluating each of OTX-CSI (cyclosporine intracanalicular insert) for the chronic treatment of dry eye disease and OTX-DED (dexamethasone intracanalicular insert) for the short-term treatment of the signs and symptoms of dry eye disease in Phase 2 clinical trials. Also, in collaboration with Regeneron, OTX-AFS (aflibercept suprachoroidal injection) is in pre-clinical development as an extended-delivery formulation of aflibercept for the treatment of retinal diseases. Ocular Therapeutix's first product, ReSure^® Sealant, is an FDA-approved device to prevent wound leaks in corneal incisions following cataract surgery.

Forward Looking Statements

Any statements in this press release about future expectations, plans, and prospects for the Company, including the commercialization of DEXTENZA^®, ReSure^® Sealant, or any of the Company’s product candidates; the commercial launch of, and effectiveness of reimbursement codes for, DEXTENZA; the conduct of post-approval studies of and compliance with related labeling requirements for DEXTENZA and ReSure Sealant; the development and regulatory status of the Company’s product candidates, such as the Company’s development of and prospects for approvability of DEXTENZA for additional indications including the PDUFA target action date scheduled for October 18, 2021 for allergic conjunctivitis, OTX-CSI for the chronic treatment of dry eye disease, OTX-DED for the short-term treatment of the signs and symptoms of dry eye disease, OTX-TIC for the treatment of primary open-angle glaucoma or ocular hypertension, OTX-TKI for the treatment of retinal diseases including wet AMD, and OTX-AFS as an extended-delivery formulation of the VEGF trap aflibercept for the treatment of retinal diseases including wet AMD; the ongoing development of the Company’s extended-delivery hydrogel depot technology; the size of potential markets for our product candidates; the potential utility of any of the Company’s product candidates; the potential benefits and future operation of the collaboration with Regeneron Pharmaceuticals, including any potential future payments thereunder; projected net product revenue, in-market sales and other financial and operational metrics of DEXTENZA; potential market sizes for indications targeted by the Company’s product candidates, if approved; the expected impact of the COVID-19 pandemic on the Company and its operations; the sufficiency of the Company’s cash resources and other statements containing the words "anticipate," "believe," "estimate," "expect," "intend", "goal," "may", "might," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors. Such forward-looking statements involve substantial risks and uncertainties that could cause the Company’s clinical development programs, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the timing and costs involved in commercializing DEXTENZA, ReSure Sealant or any product candidate that receives regulatory approval, including the conduct of post-approval studies, the ability to retain regulatory approval of DEXTENZA, ReSure Sealant or any product candidate that receives regulatory approval, the ability to maintain reimbursement codes for DEXTENZA, the initiation, timing, conduct and outcomes of clinical trials, availability of data from clinical trials and expectations for regulatory submissions and approvals, the Company’s scientific approach and general development progress, the availability or commercial potential of the Company’s product candidates, the Company’s ability to generate its projected net product revenue and in-market sales on the timeline expected, if at all, the sufficiency of cash resources, the Company’s existing indebtedness, the ability of the Company’s creditors to accelerate the maturity of such indebtedness upon the occurrence of certain events of default, the severity and duration of the COVID-19 pandemic including its effect on the Company’s and relevant regulatory authorities’ operations, any additional financing needs and other factors discussed in the “Risk Factors” section contained in the Company’s quarterly and annual reports on file with the Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent the Company’s views as of the date of this press release. The Company anticipates that subsequent events and developments will cause the Company’s views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so, whether as a result of new information, future events or otherwise, except as required by law. These forward-looking statements should not be relied upon as representing the Company’s views as of any date subsequent to the date of this press release.

Investors

Ocular Therapeutix

Donald Notman

Chief Financial Officer

dnotman@ocutx.com

or

Westwicke, an ICR Company

Chris Brinzey, 339-970-2843

Managing Director

chris.brinzey@westwicke.com

Media

Ocular Therapeutix

Scott Corning

Senior Vice President, Commercial

scorning@ocutx.com

Ocular Therapeutix, Inc.

Consolidated Statements of Operations and Comprehensive Loss

(In thousands, except share and per share data)

(unaudited)

	Three Months Ended March 31,
	2021			2020
Revenue:
Product revenue, net	$	7,342		$	2,609
Total revenue, net		7,342			2,609
Costs and operating expenses:
Cost of product revenue		892			819
Research and development		10,927			6,098
Selling and marketing		8,086			7,130
General and administrative		7,665			5,176
Total costs and operating expenses		27,570			19,223
Loss from operations		(20,228	)		(16,614	)
Other income (expense):
Interest income		12			139
Interest expense		(1,679	)		(1,633	)
Change in fair value of derivative liability		25,016			(3,404	)
Total other income (expense), net		23,349			(4,898	)
Net income (loss) attributable to common stockholders	$	3,121		$	(21,512	)
Net income (loss) per share, basic	$	0.04		$	(0.41	)
Weighted average common shares outstanding, basic		76,071,017			51,900,882
Net income (loss) per share, diluted	$	(0.24	)	$	(0.41	)
Weighted average common shares outstanding, diluted		87,245,706			51,900,882

OCULAR THERAPEUTIX, INC.

Consolidated Balance Sheets

(In thousands, except share and per share data)

(unaudited)

	March 31,			December 31,
	2021			2020
Assets
Current assets:
Cash and cash equivalents	$	209,378		$	228,057
Accounts receivable, net		13,631			12,252
Inventory		1,123			1,201
Prepaid expenses and other current assets		4,000			4,650
Total current assets		228,132			246,160
Property and equipment, net		7,527			8,095
Restricted cash		1,764			1,764
Operating lease assets		5,617			5,844
Total assets	$	243,040		$	261,863
Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable	$	4,152		$	2,709
Accrued expenses and other current liabilities		13,574			14,307
Operating lease liabilities		1,421			1,358
Notes payable, net of discount, current		8,290			8,290
Total current liabilities		27,437			26,664
Other liabilities:
Operating lease liabilities, net of current portion		7,169			7,548
Derivative liability		73,297			98,313
Deferred revenue		12,000			12,000
Notes payable, net of discount		14,907			16,936
2026 convertible notes, net		24,822			24,307
Total liabilities		159,632			185,768
Commitments and contingencies
Stockholders’ equity (deficit):
Preferred stock, $0.0001 par value; 5,000,000 shares authorized and no shares issued or outstanding at March 31, 2021 and December 31, 2020, respectively		—			—
Common stock, $0.0001 par value; 100,000,000 shares authorized and 76,236,710 and 75,996,732 shares issued and outstanding at March 31, 2021 and December 31, 2020, respectively		8			8
Additional paid-in capital		619,530			615,338
Accumulated deficit		(536,130	)		(539,251	)
Total stockholders’ equity		83,408			76,095
Total liabilities and stockholders’ equity	$	243,040		$	261,863

EX-101.SCH 3 ocul-20210505.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 ocul-20210505_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 ocul-20210505_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 6 tm2115217d1_8k_htm.xml IDEA: XBRL DOCUMENT 0001393434 2021-05-05 2021-05-05 iso4217:USD shares iso4217:USD shares 0001393434 false 8-K 2021-05-05 OCULAR THERAPEUTIX, INC. DE 001-36554 20-5560161 24 Crosby Drive Bedford MA 01730 781 357-4000 false false false false Common Stock, $0.0001 par value per share OCUL NASDAQ false XML 7 R1.htm IDEA: XBRL DOCUMENT

Cover	May 05, 2021
Cover [Abstract]
Document Type	8-K
Amendment Flag	false
Document Period End Date	May 05, 2021
Entity File Number	001-36554
Entity Registrant Name	OCULAR THERAPEUTIX, INC.
Entity Central Index Key	0001393434
Entity Tax Identification Number	20-5560161
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	24 Crosby Drive
Entity Address, City or Town	Bedford
Entity Address, State or Province	MA
Entity Address, Postal Zip Code	01730
City Area Code	781
Local Phone Number	357-4000
Written Communications	false
Soliciting Material	false
Pre-commencement Tender Offer	false
Pre-commencement Issuer Tender Offer	false
Title of 12(b) Security	Common Stock, $0.0001 par value per share
Trading Symbol	OCUL
Security Exchange Name	NASDAQ
Entity Emerging Growth Company	false

EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.1 html 1 96 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://ocutx.com/role/Cover Cover Cover 1 false false All Reports Book All Reports tm2115217d1_8k.htm ocul-20210505.xsd ocul-20210505_lab.xml ocul-20210505_pre.xml tm2115217d1_ex99-1.htm http://xbrl.sec.gov/dei/2020-01-31 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "tm2115217d1_8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "definitionLink": { "remote": [ "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml", "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml" ] }, "inline": { "local": [ "tm2115217d1_8k.htm" ] }, "labelLink": { "local": [ "ocul-20210505_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml" ] }, "presentationLink": { "local": [ "ocul-20210505_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml" ] }, "schema": { "local": [ "ocul-20210505.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd", "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2020-01-31": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 96, "memberCustom": 0, "memberStandard": 0, "nsprefix": "ocul", "nsuri": "http://ocutx.com/20210505", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm2115217d1_8k.htm", "contextRef": "From2021-05-05to2021-05-05", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://ocutx.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm2115217d1_8k.htm", "contextRef": "From2021-05-05to2021-05-05", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://ocutx.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://ocutx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://ocutx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://ocutx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://ocutx.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://ocutx.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://ocutx.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://ocutx.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r9", "r11", "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://ocutx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://ocutx.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://ocutx.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://ocutx.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://ocutx.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://ocutx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://ocutx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://ocutx.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://ocutx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://ocutx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://ocutx.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://ocutx.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://ocutx.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://ocutx.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://ocutx.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://ocutx.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://ocutx.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://ocutx.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://ocutx.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://ocutx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://ocutx.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://ocutx.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://ocutx.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://ocutx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://ocutx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://ocutx.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://ocutx.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://ocutx.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://ocutx.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://ocutx.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://ocutx.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://ocutx.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://ocutx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://ocutx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://ocutx.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://ocutx.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://ocutx.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://ocutx.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://ocutx.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://ocutx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://ocutx.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://ocutx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://ocutx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://ocutx.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://ocutx.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://ocutx.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://ocutx.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://ocutx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://ocutx.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://ocutx.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r10": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r11": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r12": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r13": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r14": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r15": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r16": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r17": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r18": { "Name": "Securities Act", "Number": "Section", "Publisher": "SEC", "Section": "12" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r9": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" } }, "version": "2.1" } ZIP 14 0001104659-21-061700-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-21-061700-xbrl.zip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�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end